Promising Results for Rituximab Treatment for Acquired Hemophilia A
Treating acquired hemophilia A (AHA) with anti CD20 monoclonal antibody Rituximab is increasingly popular, according to a case study published in the Mediterranean Journal of Hematology and Infectious Diseases.